Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Total Current Liabilities data on record, last reported at $50.7 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 22.56% year-over-year to $50.7 million; the TTM value through Sep 2025 reached $50.7 million, up 22.56%, while the annual FY2024 figure was $47.9 million, 79.74% up from the prior year.
  • Total Current Liabilities reached $50.7 million in Q3 2025 per VRDN's latest filing, down from $52.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $52.6 million in Q2 2025 and bottomed at $13.6 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $29.0 million, with a median of $25.9 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: soared 150.33% in 2021, then dropped 20.13% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $13.6 million in 2021, then soared by 144.57% to $33.3 million in 2022, then dropped by 20.13% to $26.6 million in 2023, then surged by 79.74% to $47.9 million in 2024, then increased by 5.89% to $50.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $50.7 million in Q3 2025, $52.6 million in Q2 2025, and $47.9 million in Q4 2024.